Beyond scoring: a modern interpretation of disease progression in chronic liver disease
The DOI matches its Crossref record; 90 of the 91 references it cites were found in a registry or an index.
Abstract
The progressive understanding of the natural history of chronic liver diseases (CLD) and the relative pathophysiological mechanisms have led to important improvements in the current management of these disorders. As for any cognitive course, this progress has been based on the establishment of identifiable endpoints. Along these lines, the introduction of staging systems based on the histopathological assessment of liver tissue fibrosis has allowed a reasonable understanding of what is defined as disease progression in CLD, and has facilitated the communication between clinicians and pathologists. However, there is increasing awareness that a simple semiquantitative fibrosis score does not adequately represent the complexity of the pathophysiological process leading to cirrhosis, and ultimately to life-threatening complications. Indeed, the categorisation in fibrosis stages is a clinical compromise that does not reflect the biological complexity of disease progression. This inadequacy becomes fully manifested in the stage defined ‘cirrhosis’, a phase of CLD often lasting several years, lacking appropriate clinical–pathological correlates.1 ,2 All these issues, and particularly those related to cirrhosis, are currently magnified by the increasing availability of potentially effective causative treatments (ie, antiviral agents for HCV and HBV CLD) with the emerging need of assessing/predicting disease stabilisation or even disease regression with relative accuracy. The aim of this article is to analyse this evolving area of hepatology, and focus on some relevant areas of research which will likely bring further advancement in the near future. In particular, the progression of CLD should be analysed according to aetiology-driven mechanisms, and by integrating the results of invasive and non-invasive methods with a clear mission towards the identification of predictive indexes guiding a more effective clinical management. Further complexity has been introduced by the recent description of the entity termed ‘acute on chronic liver failure’ (ACLF) which refers to a very rapid progression of …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Earlier stages of MASH fibrosis can regress more easily than advanced stages, a trend observed in other liver diseases (260), which may be explained in part by the marked increase in total collagen and extracellular matrix associated with progressive fibrosis (261).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [261]
Citations
Cites
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Rifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300
Arvaniti, V., D'Amico, G., Fede, G., Manousou, P., Tsochatzis, E., Pleguezuelo, M., & Burroughs, A. K. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.019 · Cited by 1,167
Berg, R. D., & Garlington, A. W. (1979) · Infection and Immunity · doi:10.1128/iai.23.2.403-411.1979 · Cited by 841
Bernard, B., Grangé, J.-D., Khac, E. N., Amiot, X., Opolon, P., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510290608 · Cited by 836
The clinical use of HVPG measurements in chronic liver disease
Bosch, J., Abraldes, J. G., Berzigotti, A., & García-Pagan, J. C. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.149 · Cited by 727
Research works printed but not linked: 1
- Gonzalez-Navajas, 2007, Bacterial DNA in patients with cirrhosis and sterile ascites. Its role as a marker of bacterial translocation and prognostic tool, Rev Esp Enferm Dig, 99, 599
Cited by
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Self-citationAcute-on chronic liver failure
Jalan, R., Gines, P., Olson, J. C., Mookerjee, R. P., Moreau, R., Garcia-Tsao, G., Arroyo, V., & Kamath, P. S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.026 · Cited by 646
Self-citationNon-invasive evaluation of portal hypertension using ultrasound elastography
Berzigotti, A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.003 · Cited by 271
“Portal Hypertension in patients with CLD In CLD the liver features a progressive accumulation of extracellular matrix (fibrogenesis); in “advanced” CLD (8, 9), fibrosis is accompanied by a more complex derangement of intrahepatic”
BackgroundPeng, J.-K., Hepgul, N., Higginson, I. J., & Gao, W. (2019) · Palliative Medicine · doi:10.1177/0269216318807051 · Cited by 283
The clinical course of cirrhosis: The importance of multistate models and competing risks analysis
Jepsen, P., Vilstrup, H., & Andersen, P. K. (2015) · Hepatology · doi:10.1002/hep.27598 · Cited by 194
“Therefore, multistate models are highly relevant for studies of patients with cirrhosis whose clinical course is fraught with complications—for example, infections, ascites, variceal bleeding, hepatic encephalopathy, acute-on-chronic liver failure, hepatocellular carcinoma (HCC), and death.(2,3) It is increasingly cle…”
Background
Metadata
- Authors
- Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M.
- Affiliations
- The Royal Free Hospital (GB)
- Corresponding author
- Pinzani, Massimo
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2013-05-05
- Volume
- 62
- Issue
- 9
- Pages
- 1234-1241
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2097157805
- Cited by
- 96
- References
- 91
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 5 · 2018: 12 · 2017: 7 · 2016: 4 · 2015: 19 · 2014: 15
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- chronic liver disease, disease progression, liver fibrosis, fibrosis staging, liver cirrhosis, natural history (disease), histopathological assessment, noninvasive fibrosis assessment, antiviral therapy, hepatitis C, hepatitis B, acute-on-chronic liver failure, disease regression, predictive index
- MeSH terms
- Collagen, Fibrosis, Humans, Intestinal Diseases, Liver, Liver Cirrhosis, Liver Regeneration, Prognosis, Disease Progression, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beyond scoring: a modern interpretation of disease progression in chronic liver disease. https://app.cochat.ai/papers/10.1136/gutjnl-2012-302826
- The paper
- Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013). Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut. https://doi.org/10.1136/gutjnl-2012-302826
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.